Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic.

Maddalena GiannellaStefano VerardiAndreas KarasHasania Abdel HadiHervé DupontAlex SorianoAnne Santerre HenriksenAndrew CooperMarco Falconenull null

Published in: Open forum infectious diseases (2023)

Despite use in complex patients with limited treatment options and high septic shock/COVID-19 rates, cefiderocol treatment was associated with an overall clinical success rate of 53%.

Keyphrases

septic shock
gram negative
coronavirus disease
sars cov
acinetobacter baumannii
replacement therapy